TVTX
Travere Therapeutics, Inc. · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers):
breedte van houders +7.7% ·
aandelenstroom +30.0% ·
netto nieuwe posities +7.1%
— formule
Brede accumulatie — stijgende aandelen bij meer houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q4 2024
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 113 | +16 | 68.16M | $3.63B | +20 | −4 |
| Q1 2026 | 100 | -5 | 69.82M | $2.07B | +9 | −14 |
| Q4 2025 | 104 | +1 | 74.66M | $2.85B | +1 | — |
| Q3 2025 | 21 | +1 | 36.01M | $860.71M | +2 | −2 |
| Q2 2025 | 18 | +1 | 30.33M | $448.83M | +2 | −1 |
| Q1 2025 | 14 | 0 | 16.78M | $300.70M | — | — |
| Q4 2024 | 14 | +1 | 16.09M | $280.22M | +2 | −1 |
| Q3 2024 | 12 | -1 | 7.80M | $109.09M | +1 | −2 |
| Q2 2024 | 13 | — | 10.32M | $84.85M | — | — |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passief) | 3.77M | — | $65.63M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Viking Global Investors ✦ | 2.90M | Nieuw | $50.55M | 0.2% | New | 1 | SEC ↗ |
| 3 | Renaissance Technologies ✦ | 2.41M | +28.5% | $41.97M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 4 | D. E. Shaw & Co. ✦ | 2.28M | +23.8% | $39.69M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | D. E. Shaw & Co. ✦ | 2.28M | +23.8% | $39.69M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passief) | 1.84M | +6.4% | $32.10M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passief) | 1.84M | +6.4% | $32.10M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 693.02K | +92.5% | $12.07M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | Millennium Management ✦ | 626.06K | +446.2% | $10.91M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 579.14K | -25.3% | $10.09M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 579.14K | -25.3% | $10.09M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 424.02K | +117.8% | $7.39M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 424.02K | +117.8% | $7.39M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 424.02K | +117.8% | $7.39M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 424.02K | +117.8% | $7.39M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 16 | Adage Capital Partners ✦ | 376.80K | -5.8% | $6.56M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | Norges Bank ✦ (passief) | 71.00K | 0.0% | $1.24M | 0.0% | Held | 3 | SEC ↗ |
| 18 | Fisher Asset Management ✦ | 43.18K | 0.0% | $752,230 | 0.0% | Held | 3 | SEC ↗ |
| 19 | T. Rowe Price ✦ | 39.60K | -85.9% | $690,000 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 20 | Wellington Management ✦ | 33.49K | Nieuw | $583,449 | 0.0% | New | 1 | SEC ↗ |
| 21 | Wellington Management ✦ | 33.49K | Nieuw | $583,449 | 0.0% | New | 1 | SEC ↗ |
| 22 | Wellington Management ✦ | 33.49K | Nieuw | $583,449 | 0.0% | New | 1 | SEC ↗ |
| 23 | Wellington Management ✦ | 33.49K | Nieuw | $583,449 | 0.0% | New | 1 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Viking Global Investors | $50.55M | 0.2% |
| Wellington Management | $583,449 | 0.0% |
| Wellington Management | $583,449 | 0.0% |
| Wellington Management | $583,449 | 0.0% |
| Wellington Management | $583,449 | 0.0% |
Verlaten
| Marshall Wace | $1.56M | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 1 houders, 121.20K aandelen, $3,600 gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Director · 4.10K aand · $259,390
Director · 900 aand · $57,470
Director · 500 aand · $32,081
Director · 1.90K aand · $118,805
Director · 2.60K aand · $165,100
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie